Achieving Equitable Representation in Clinical Studies

The panel has an in-depth discussion on improving diversity in clinical trials. They discuss ways to increase minority participation through community partnerships, including providing transportation, lodging, and other resources needed to enable participation.

EP: 1.Disparities in Cardiovascular Care for Diverse Populations

EP: 2.Innovation vs Access: Supporting Underserved Communities

EP: 3.Exploring Polypharmacy: Adherence, Communication, and Outcomes

EP: 4.Gender-Based Disparities in Cardiovascular Disease

EP: 5.Peripheral Arterial Disease Awareness for Minority Populations

EP: 6.Community Partnership: Increasing Public Awareness of CVD

EP: 7.Recent Data Reveals Disparities in Cardiovascular Care

EP: 8.Identifying Social Determinants of Health in Cardiovascular Care

EP: 9.Impact of Novel Medications and Out-Of-Pocket Costs in Managing Cardiovascular Disease

EP: 10.Developing Practical Solutions to Improve Cardiovascular Care

EP: 11.Advancing Cardiovascular Care Through Technological Innovation

EP: 12.Desired Technology Innovations to Prevent Cardiovascular Disease

EP: 13.Measuring Implicit Bias

Now Viewing

EP: 14.Achieving Equitable Representation in Clinical Studies

EP: 15.Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion

Related Videos

Related Content

Advertisement

July 26th 2024

Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors

Sabrina Serani

The Alliance AO91902 trial investigated whether adding immunotherapy to chemotherapy would improve outcomes for patients with advanced angiosarcoma.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

July 26th 2024

Hemophilia A Gene Therapy Superior to Standard of Care in Phase 3 Trial

Laura Joszt, MA

The gene therapy giroctocogene fitelparvovec demonstrated superiority compared with the standard of care, routine prophylaxis, in hemophilia A treatment.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

July 25th 2024

Dr Diane Mahoney on Tackling Ovarian Cancer Care Disparities

Brooke McCormick

In part 2 of our interview, Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, advocates for a multidisciplinary, community-centered approach to reduce ovarian cancer care disparities and stresses the need for ongoing exploration of social, biological, and environmental factors affecting health outcomes.

July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

Related Content

Advertisement

July 26th 2024

Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors

Sabrina Serani

The Alliance AO91902 trial investigated whether adding immunotherapy to chemotherapy would improve outcomes for patients with advanced angiosarcoma.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

July 26th 2024

Hemophilia A Gene Therapy Superior to Standard of Care in Phase 3 Trial

Laura Joszt, MA

The gene therapy giroctocogene fitelparvovec demonstrated superiority compared with the standard of care, routine prophylaxis, in hemophilia A treatment.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

July 25th 2024

Dr Diane Mahoney on Tackling Ovarian Cancer Care Disparities

Brooke McCormick

In part 2 of our interview, Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, advocates for a multidisciplinary, community-centered approach to reduce ovarian cancer care disparities and stresses the need for ongoing exploration of social, biological, and environmental factors affecting health outcomes.

July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.